HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jonathan C Strefford Selected Research

B-Cell Antigen Receptors (B Cell Antigen Receptors)

10/2021Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
1/2021DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.
9/2016The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jonathan C Strefford Research Topics

Disease

15B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/2022 - 01/2013
10Neoplasms (Cancer)
04/2022 - 01/2008
5Lymphoma (Lymphomas)
04/2022 - 01/2019
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
10/2021 - 01/2019
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/2011 - 11/2006
2Disease Progression
10/2021 - 01/2018
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2021 - 10/2021
1Hypoxia (Hypoxemia)
04/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
10/2021
1Hypersensitivity (Allergy)
01/2019
1Trisomy (Trisomies)
09/2016
1Adenocarcinoma
01/2016
1Lymphocytosis
06/2015
1Cytokine Release Syndrome
01/2015

Drug/Important Bio-Agent (IBA)

6Monoclonal AntibodiesIBA
04/2022 - 01/2015
5AntigensIBA
02/2022 - 01/2019
4Biological ProductsIBA
01/2019 - 01/2016
4fludarabineIBA
12/2016 - 01/2013
3B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA
10/2021 - 09/2016
3Rituximab (Mabthera)FDA Link
10/2021 - 02/2016
3obinutuzumabIBA
10/2021 - 01/2019
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2016 - 01/2013
2DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
10/2021 - 01/2021
2GalliumIBA
10/2021 - 01/2019
2anti-IgMIBA
01/2021 - 01/2016
2Immunoglobulins (Immunoglobulin)IBA
01/2019 - 01/2016
2Phosphotransferases (Kinase)IBA
05/2017 - 01/2016
2ibrutinibIBA
05/2017 - 01/2016
2Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
01/2008 - 11/2006
1Immunoglobulin M (IgM)IBA
01/2022
1LectinsIBA
10/2021
1Mechanistic Target of Rapamycin Complex 1IBA
10/2021
1Intercellular Adhesion Molecule-3IBA
10/2021
1Polysaccharides (Glycans)IBA
10/2021
1Complementarity Determining Regions (Complementarity Determining Region)IBA
10/2021
1IntegrinsIBA
10/2021
1Glucose (Dextrose)FDA LinkGeneric
10/2021
1Immunoglobulin Variable RegionIBA
10/2021
1NucleotidesIBA
10/2021
1Chimeric Antigen ReceptorsIBA
01/2021
1Bendamustine HydrochlorideFDA Link
01/2019
1serum P-component (CIt)IBA
01/2019
1RNA (Ribonucleic Acid)IBA
01/2018
1DNA (Deoxyribonucleic Acid)IBA
01/2018
1Janus Kinase InhibitorsIBA
05/2017
14- (cyclopropylamino)- 2- ((4- (4- (ethylsulfonyl)piperazin- 1- yl)phenyl)amino)pyrimidine- 5- carboxamideIBA
05/2017
1Pharmaceutical PreparationsIBA
12/2016
1ChromatinIBA
01/2016
1Interleukin-4 (Interleukin 4)IBA
01/2016
1idelalisibIBA
01/2016
12- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA
06/2015
1IgG Receptors (Fc gamma RI)IBA
01/2015
1TGN-1412 (TGN1412)IBA
01/2015
1Cytochrome P-450 CYP2B6 (CYP2B6)IBA
12/2013
1Chlorambucil (Leukeran)FDA Link
01/2013
1Cytokine Receptors (Cytokine Receptor)IBA
09/2009

Therapy/Procedure

4Drug Therapy (Chemotherapy)
10/2021 - 12/2013
3Immunotherapy
04/2022 - 01/2015
1Therapeutics
06/2011